A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine

Frontiers in Psychiatry
Daniela Rodrigues-AmorimTania Rivera-Baltanás

Abstract

Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of patients affected by major depressive disorder (MDD), generalized anxiety disorder (GAD), neuropathic pain (NP), fibromyalgia (FMS), and stress incontinence urinary (SUI). These conditions share parallel pathophysiological pathways, and duloxetine treatment might be an effective and safe alternative. Thus, a systematic review was conducted following the 2009 Preferred Reporting Items (PRISMA) recommendations and Joanna Briggs Institute Critical (JBI) Appraisals guidelines. Eighty-five studies focused on efficacy, safety, and tolerability of duloxetine were included in our systematic review. Studies were subdivided by clinical condition and evaluated individually. Thus, 32 studies of MDD, 11 studies of GAD, 19 studies of NP, 9 studies of FMS, and 14 studies of SUI demonstrated that the measured outcomes indicate the suitability of duloxetine in the treatment of these clinical conditions. This systematic review confirms that the dual mechanism of duloxetine benefits the treatment of comorbid clinical conditions, and supports the efficacy, safety, and tolerability of duloxetine in short- and long-term treatments.

References

Feb 9, 2000·Journal of Clinical Pharmacology·A SharmaB J Cerimele
Apr 3, 2002·The Journal of Clinical Psychiatry·David J GoldsteinMark A Demitrack
May 10, 2002·The Journal of Clinical Psychiatry·Michael J DetkeMark A Demitrack
Dec 14, 2002·CNS Drug Reviews·Kelly D KarpaJoan M Lakoski
Jun 18, 2003·Archives of Dermatology·Michael Bigby, Hywel Williams
Sep 23, 2003·The Journal of Urology·Roger R DmochowskiUNKNOWN Duloxetine Urinary Incontinence Study Group
Feb 7, 2004·BJU International·R J MillardUNKNOWN Duloxetine UI Study Group
Feb 14, 2004·BJOG : an International Journal of Obstetrics and Gynaecology·Philip van KerrebroeckUNKNOWN Duloxetine Urinary Incontinence Study Group
Mar 5, 2004·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Bruce Nicholson, Sunil Verma
Jul 3, 2004·Journal of Clinical Psychopharmacology·David J GoldsteinMark A Demitrack
Sep 2, 2004·Obstetrics and Gynecology·Linda CardozoRichard C Bump
Jan 22, 2005·International Urogynecology Journal and Pelvic Floor Dysfunction·Kraig S KinchenRalph Swindle
Apr 12, 2005·The Journal of Urology·Gamal M GhoniemUNKNOWN Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group
Jun 2, 2005·Pain·David J GoldsteinSmriti Iyengar
Sep 28, 2005·Diabetes Care·Loretta VileikyteAndrew J M Boulton
Nov 4, 2005·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Joel RaskinJoachim F Wernicke
Jan 5, 2006·The American Journal of Psychiatry·Madhukar H TrivediUNKNOWN STAR*D Study Team
Apr 4, 2006·The British Journal of Psychiatry : the Journal of Mental Science·David G PerahiaMichael J Detke
May 9, 2006·Journal of Psychiatric Research·Maurizio FavaDavid Perahia
May 16, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·D G S PerahiaM J Detke
Sep 12, 2006·Primary Care Companion to the Journal of Clinical Psychiatry·J Craig NelsonMichael J Detke
Sep 13, 2006·The Journal of Clinical Psychiatry·Lesley M ArnoldEvelyn V Hess
Oct 4, 2006·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Joel RaskinDavid J Goldstein
Dec 13, 2006·International Urogynecology Journal and Pelvic Floor Dysfunction·David Castro-DiazUNKNOWN Duloxetine Dose Escalation Study Group
Dec 19, 2006·Lancet·Peter Tyrer, David Baldwin
Apr 7, 2007·International Clinical Psychopharmacology·James HartfordJanelle Erickson
Jun 15, 2007·Current Medical Research and Opinion·Teresa A PigottMadelaine M Wohlreich
Jun 21, 2007·Neurourology and Urodynamics·Alfred E BentRichard C Bump
Jun 26, 2007·International Journal of Clinical Practice·T N WiseJ Raskin
Jul 31, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·David G ArmstrongJames M Russell
Oct 17, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Lesley M Arnold
Aug 25, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Joachim F WernickeAmy S Chappell
Jan 22, 2008·Journal of Clinical Psychopharmacology·Joel RaskinCornelius Katona
Mar 7, 2008·The New England Journal of Medicine·Rebecca G Rogers

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Revue de l'infirmière
Corinne Taéron
Journal of Psychiatric Practice
Sheldon H Preskorn
BJOG : an International Journal of Obstetrics and Gynaecology
M OelkeMartin C Michel
Journal of Pain Research
Beth A ScholzChad S Boomershine
© 2021 Meta ULC. All rights reserved